Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

New Bone Cutting Technology from Finnish Startup Surgify

Finnish startup Surgify that recently launched an all-new and innovative surgical technology which allows surgeons to perform surgical operations on bones faster and safer has seen its first use cases on patients.

Surgify’s flagship cutting technology is a result of diligent development work. The first surgeries were successfully performed in October 2021 at Helsinki University Hospital (HUS), and the results are extremely promising.

“The two surgical patients recovered well from their surgeries and returned home quickly. Neither faced soft tissue damage during the operation,” says Head of HUS Neurosurgery and Professor Mika Niemelä.

Surgify’s technology cuts bone while preventing injuries to easily damageable soft tissues such as meninges, muscles, blood vessels, nerve pathways, or central nervous system structures. Depending on the type of surgery, the risk of soft tissue damage can be up to 30 percent. With Surgify’s technology, such injuries can possibly be avoided entirely. Severe soft tissue damage can, at worst, result in permanent injury or patient death.

“Surgify’s device appears to push the soft tissue out of the way. This is a major advantage, as a typical surgical drill that spins tens of thousands of times in a minute can be very dangerous if it touches soft tissue,” adds Niemelä.

Clinical procedures with Surgify’s new technology will continue at HUS.

Innovation that results in millions in savings for hospitals and paves the way for the use of robotics

Surgify’s technology can potentially save hospitals up to €3 million a year, thanks to the prevention of complications and lessened need for continued care. When the soft tissue is not damaged, the patient needs less treatment, recovers faster, and postoperative complications are less likely.

Soft tissue damage is particularly common in the elderly, as the tissue in older patients is naturally more fragile. As the number of elderly patients increases, so do the risks. Globally, such complications cost nearly €4 billion, and as the population ages, this can be expected to grow without innovative solutions.

New technological devices are making a breakthrough in medical care. Already today, robots are used to operate some parts of the surgery. Surgify’s technology is perfectly suitable for both traditional handheld surgeries as well as surgical robotics.

“We see our solution as part of a bigger change that is happening in surgery, and that enables wider use of automation in many types of procedures. We envision enabling surgeons to perform their surgical skills beyond the limitations of current surgical instrumentation, allowing best-in-class surgical procedures for every patient and cost-efficient innovation for the health system,” says Surgify’s CEO, Visa Sippola.

Next, Surgify targets the international market with its product. Their internationalization strategy is sharpened by their newly appointed Chair of Board, Lex R. Giltaij MD MBA. He has been serving for more than 30 years in senior executive positions creating and building international businesses for many orthopedic and spinal companies, amongst them Stryker, St. Francis Medical Technology (now Medtronic), and Pioneer Surgical (now RTI Surgical).

“We’re starting in the Nordic countries and will soon take our groundbreaking technology to the international markets in the EU and USA. We are also looking forward to continuing our effective collaboration work with HUS,” Giltaij concludes.

View all news here.

SourceSurgify
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy